Integral Molecular touts Pa. grant to advance COVID-19 research

By The Science Advisory Board staff writers

September 21, 2020 -- Integral Molecular was awarded over $520,000 from the state of Pennsylvania to leverage its technologies in COVID-19 research. The grant will enable the company and its partners to develop therapies and vaccines against SARS-CoV-2.

Four of Integral Molecular's technology platforms are being used in the fight against the virus, including:

  • MPS Antibody Discovery platform to generate reactive antibodies against SARS-CoV-2 and other coronaviruses
  • SARS-CoV-2 reporter virus particles (RVPs) to test the safety for neutralizing immune responses in patients and vaccines
  • Membrane protein array (MPA) to rapidly screen for specificity of antibodies for SARS-CoV-2
  • Shotgun mutagenesis epitope mapping to optimize vaccine and antibody design

The funding was received through the state's COVID-19 Vaccines, Treatments, and Therapies (CV-VTT) program.

Integral Molecular adds to its antibody discovery platform
Integral Molecular has developed humanized chicken antibody technology and incorporated it into its MPS antibody discovery platform for multipass membrane...
Integral Molecular aids with safety testing of COVID-19 antibodies
Integral Molecular is applying its membrane proteome array technology for antibody specificity profiling to accelerate development of SARS-CoV-2 therapeutic...
Integral Molecular wins COVID-19 NIAID award
The National Institute of Allergy and Infectious Diseases (NIAID) has awarded Integral Molecular $1 million to help discover vaccines and therapeutics...

Copyright © 2020

Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter